They removed the April date from this part and itâ
Post# of 30027
b. Upon the Merger, a minimum of $6,000,000 of dedicated funds must be raised to advance
eltoprazine into Phase 2b human trials by April 23rd, 2018;
With how sloppy things have been written recently, I see this amendment as simply a clean up on the original. I’m not sure much has really changed. I haven’t had much time to analyze but that’s my hot take.